CIK: 0001766721 · Show all filings
Period: Q3 2024 (← Previous) (Next →)
Filing Date: Nov 13, 2024
Total Value ($000): $261,072 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | 6,068,125 | $154,494 | 59.2% | $40.43 | -35.1% | COM | 10806X102 |
| — | Verona Pharma plc (VRNA) | 1,115,352 | $32,089 | 12.3% | $7.38 | — | SPONSORED ADS | 925050106 |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | 1,025,000 | $19,731 | 7.6% | $10.24 | +101.8% | COM | 87164F105 |
| BCAX | Bicara Therapeutics Inc. (BCAX) | 568,919 | $14,490 | 5.6% | $25.50 | 0.0% | COM | 055477103 |
| BMEA | Biomea Fusion Inc (BMEA) | 798,757 | $8,067 | 3.1% | $17.65 | -63.2% | COM | 09077A106 |
| GLUE | Monte Rosa Therapeutics Inc (GLUE) | 1,472,331 | $7,803 | 3.0% | $20.37 | -75.2% | COM | 61225M102 |
| CMPS | Compass Pathways Plc (CMPS) | 964,500 | $6,076 | 2.3% | $7.40 | — | SPONSORED ADS | 20451W101 |
| NUVB | Nuvation Bio Inc. (NUVB) | 2,541,009 | $5,819 | 2.2% | $11.18 | -72.7% | COM CL A | 67080N101 |
| — | Poseida Therapeutics Inc. (PSTX) | 1,043,267 | $2,984 | 1.1% | $8.87 | — | COM | 73730P108 |
| TECX | Tectonic Therapeutic Inc (TECX) | 84,148 | $2,550 | 1.0% | $15.77 | +15.9% | COM | 878972108 |
| CALC | CalciMedica, Inc. (CALC) | 521,114 | $2,309 | 0.9% | $4.55 | -3.4% | COM NEW | 38942Q202 |
| — | Elevation Oncology Inc (ELEV) | 2,834,910 | $1,701 | 0.7% | $13.57 | — | COM | 28623U101 |
| — | Reneo Pharmaceuticals Inc (RPHM) | 886,075 | $1,506 | 0.6% | $9.33 | — | COM | 75974E103 |
| MRKR | Marker Therapeutics, Inc. (MRKR) | 314,286 | $886 | 0.3% | $1.74 | +127.6% | COM NEW | 57055L206 |
| ACRS | Aclaris Therapeutics Inc (ACRS) | 434,455 | $500 | 0.2% | $10.31 | -88.1% | COM | 00461U105 |
| — | Viracta Therapeutics Inc (VIRX) | 288,571 | $66 | 0.0% | $11.34 | — | COM | 92765F108 |